Plain-English translation of NCT06841354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Triple Negative Breast Neoplasms research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , given alone or combined with , can help people with advanced triple-negative breast cancer live longer and keep their cancer from growing. Triple-negative breast cancer is a type that doesn't respond to some common hormone-based treatments, making it harder to treat. Researchers want to see if this medication works better than the standard chemotherapy options doctors typically use.
Triple-negative breast cancer is aggressive and has limited treatment options. This trial exists to see whether the new treatment approach might give patients better outcomes and longer survival than the chemotherapy treatments currently available.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication alone, the new medication combined with another drug, or standard chemotherapy. If you receive the new treatment, you will get intravenous infusions every two weeks for as long as the medication works and you tolerate it well. You will need regular visits to the research center for treatment infusions, blood tests, and scans to check how your cancer is responding. The study will continue until your cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States